BCL2 and synovial sarcoma: Bcl-2 positivity, as assessed by IHC, is an almost general constitutive alteration of SS, although it is typically largely restricted to the spindle cell component, in contrast to the preferential expression in the epithelial component in our case [15,30]. BCL-2 (located on 18q21.33) is also in close proximity to SS18. While commonly overexpressed in SS, bcl-2 upregulation seems independent of amplification (or rearrangement) at the genomic level [21].